Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial
Biomolecules · 01.01.2025 · 15 (1) · 46
DOI: 10.3390/biom15010046 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Biomolecules, online erschienen am 01.01.2025. Verfasst von Jelena Petković-Dabić und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Psoriasis, Obesity. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Psoriasis is a chronic inflammatory skin disease with relapsing nature. Estimates are that approximately 2–3% of the world’s population suffers from this disease. More severe forms of psoriasis are conditions of high inflammation, which is confirmed by the clinical picture and numerous inflammatory parameters such as C-reactive protein (CRP), cytokines and homocysteine, which vary with disease activity. The objective of this clinical study was to investigate the effect of GLP-1 receptor agonist semaglutide therapy on pro-inflammatory factors in the serum and the severity of the clinical picture of psoriasis in obese patients with type 2 diabetes mellitus (T2DM) on chronic metformin therapy. This randomized clinical study was conducted on 31 psoriatic patients with T2DM that were randomized into two groups: one that received semaglutide during the 12-week trial (n = 15), while the second was control (n = 16). The results demonstrated that the severity of the clinical picture of psoriasis, determined by the Psoriasis Area and Severity Index (PASI) score, was significantly better after the administration of semaglutide (the median baseline PASI score in patients treated with semaglutide was 21 (IQR = 19.8), while after 12 weeks of therapy the score was 10 (IQR = 6; p = 0.002). Also, the quality of life in the group of patients who received the drug, measured by the Dermatology Life Quality Index (DLQI), improved significantly after 3 months (a median baseline DLQI score in the semaglutide group was 14 (IQR = 5) at the beginning of the study, and after 12 weeks of treatment the median DLQI score was 4 (IQR = 4; p = 0.002)). The use of semaglutide led to a significant decrease in pro-inflammatory cytokines in the serum (IL6), as well as a significant decrease in CRP values (p < 0.05). A significant decrease in the body mass index (BMI) value in the semaglutide-treated group was also identified, as well as a significant decrease in the level of low-density cholesterol (LDL) (p < 0.05). In conclusion, semaglutide, based on its systemic anti-inflammatory characteristics, could contribute to the treatment of psoriatic obese patients with T2DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina.
- Clinic of Skin and Venereal Diseases, University Clinical Centre of the Republic of Srpska, 78000 Banja Luka, Bosnia and Herzegovina.
- Faculty of Medicine, University of Niš, 18000 Niš, Serbia.
- Department of Internal Medicine, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina.
- Department of Microbiology and Immunology, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Bosnia and Herzegovina.
- Faculty of Medicine Foča, University of East Sarajevo, 71123 Istočno Sarajevo, Bosnia and Herzegovina.
ORCID-Profile: Ljiljana Božić, Sanja Umičević-Šipka, Miloš P Stojiljković, Ranko Škrbić
Zitieren
APA
Petković-Dabić, J., Binić, I., Carić, B., Božić, L., Umičević-Šipka, S., Bednarčuk, N., Dabić, S., Šitum, M., Popović-Pejičić, S., Stojiljković, M. P., & Škrbić, R. (2025). Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial. Biomolecules, 15(1), 46. https://doi.org/10.3390/biom15010046
Vancouver
Petković-Dabić J, Binić I, Carić B, Božić L, Umičević-Šipka S, Bednarčuk N, et al. Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial. Biomolecules. 2025;15(1):46. doi:10.3390/biom15010046
BibTeX
@article{PetkoviDabi2025,
author = {Petković-Dabić, Jelena and Binić, Ivana and Carić, Bojana and Božić, Ljiljana and Umičević-Šipka, Sanja and Bednarčuk, Nataša and Dabić, Saša and Šitum, Mirna and Popović-Pejičić, Snježana and Stojiljković, Miloš P and Škrbić, Ranko},
title = {Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {1},
pages = {46},
doi = {10.3390/biom15010046}
}
EUVIMED